Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
about
Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordomaMicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategies.Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients.Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasThe biological basis for modern treatment of chordoma.Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers.Systemic therapy options for unresectable and metastatic chordomas.Recurrent chromosomal copy number alterations in sporadic chordomas.Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.Frequent activation of EGFR in advanced chordomas.Iodine-125 seed implantation in the treatment of sacrococcygeal chordoma: a case report.Novel therapeutic targets in chordoma.Phase II study on lapatinib in advanced EGFR-positive chordoma.Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets.Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.Erlotinib inhibits growth of a patient-derived chordoma xenograft.Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12Connection between expression of inducible nitric oxide synthase (iNOS) in skull base chordoma and lower urinary tract symptoms.Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.Sustained response of a clivus chordoma to erlotinib after imatinib failure.Novel targeted therapies in chordoma: an update.The molecular aspects of chordoma.Multidisciplinary approach of lumbo-sacral chordoma: From oncological treatment to reconstructive surgery.Prognostic and Therapeutic Markers in Chordomas: A Study of 287 Tumors.EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaErlotinib resistance in lung cancer: current progress and future perspectives.AQP1 expression analysis in human diseases: implications for proteomic characterization.Targeted therapies: the rare cancer paradigm.ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.EGFR Inhibition in a Pretreated Sacral Chordoma: A Role for Erlotinib? Case Report and a Brief Review of Literature.Chordoma: a case series and review of the literature
P2860
Q28255507-090D0349-A036-486F-B23B-FF04A0325DFEQ30414321-45529FF6-7D1F-4185-8ED9-702492C5E941Q33272960-EFF0B918-0DE4-4249-8225-E8DA0514FE05Q33273364-474F2E6D-6B74-4CC3-AA5B-5AD050798EE2Q33273672-71F830D4-4478-48AF-A597-3DB2338DA9FBQ33273701-506E55B8-384F-4549-89A2-A728B7B5A843Q33274086-98797029-AF0E-49F3-AA0D-15BC042E1E82Q33274088-263634EE-6AD5-47CA-BE94-70DE7DD2C40EQ33274146-B4FE467B-FFB8-4B71-A38E-2245BACAFE72Q33274149-A98FF0D7-FE97-40D2-9F28-6BE662FBC309Q33274256-77C0A582-C5E5-4CAA-A6FA-E2C7CD8133E3Q33274473-7660B22C-192F-4A01-B1B8-A312AE86C6BAQ33274517-AC7C32D8-B47C-427C-9014-9B885452842BQ33274528-835AECCB-E273-4B7D-A0BA-7F389A8D2C88Q33274760-56F2729C-74D5-4871-9539-E727DD62B352Q33274821-F2982528-461B-4724-A25C-3969C29DBDF2Q33274913-91E5F70F-B106-4E33-BDD9-FBA373BA6BBFQ33275026-5D0C19BD-1CFD-4319-BEC8-7E3A6F5D55DCQ33275031-A506A953-D894-489C-B3C8-535F15D46B09Q33275053-6933C55D-E2C8-4A62-970F-3FE8850FAFBCQ33275360-5C4F70A6-3F81-4C9B-99E9-A35A441CB27EQ33275402-C3525E86-F082-413E-8945-0325851DCA5DQ33275576-A0BAEC72-666C-4D6B-95C4-B8D60649AF16Q33275653-E05A4ABF-D9F5-48C5-8882-862E19CBF29AQ33275745-A2B402C9-E849-44B9-8A29-079BA5A59C65Q33275786-0A33B767-B6A2-4425-8E16-EBCB567CC322Q33275854-E41BA7C2-70A2-4D39-858A-32146FFDB314Q33276007-D09B3ECF-EE14-487E-A0BC-47D585C092DDQ35108386-52D28A43-62C9-4CC4-8282-14340F8960FEQ36605522-1A71E709-1702-459D-991D-8CF4A8FCFDF8Q37087372-12CDD009-1561-46DF-8562-00D2764074DCQ37632825-FB03E39E-A2F9-4AE4-928C-61AE63E53941Q38263000-2AE86A2A-9CB1-4476-89ED-60CF794FA06DQ39263953-CCC4CAE0-584A-4F68-A6A6-7AB9F08CFAA0Q39739616-14A15216-8093-4733-BD46-A68CA3F83DF9Q41184358-941AFCE5-1AB1-4261-BABA-E7D9067BC451Q58701832-F776B26D-3510-47E4-8CF6-BD52AD34C57B
P2860
Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Differential expression of epi ...... ed with 17 other malignancies.
@ast
Differential expression of epi ...... ed with 17 other malignancies.
@en
Differential expression of epi ...... ed with 17 other malignancies.
@nl
type
label
Differential expression of epi ...... ed with 17 other malignancies.
@ast
Differential expression of epi ...... ed with 17 other malignancies.
@en
Differential expression of epi ...... ed with 17 other malignancies.
@nl
prefLabel
Differential expression of epi ...... ed with 17 other malignancies.
@ast
Differential expression of epi ...... ed with 17 other malignancies.
@en
Differential expression of epi ...... ed with 17 other malignancies.
@nl
P2093
P1433
P1476
Differential expression of epi ...... ed with 17 other malignancies.
@en
P2093
Amanda Psyrri
Clarence T Sasaki
Diane Kowalski
Phillip Manger
P304
P356
10.1001/ARCHOTOL.131.8.707
P577
2005-08-01T00:00:00Z